Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration
Authors:
- Tryfon RotsosTRTryfon Rotsos
- Praveen J PatelPPPraveen J Patel
- Fred K ChenFCFred K Chen
- Adnan TufailATAdnan Tufail
Open Access
- 1 November 2010
- journal article
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. 4, 1271-5
Abstract
Peer reviewed article authored by (Tryfon Rotsos, Praveen J Patel, Fred K Chen, et al). Read article or submit your manuscript for publishing.Keywords
This publication has 6 references indexed in Scilit:
- Results of One-Year's Treatment with Ranibizumab for Exudative Age-related Macular Degeneration in a Clinical SettingAmerican Journal of Ophthalmology, 2009
- A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO StudyAmerican Journal of Ophthalmology, 2009
- Ranibizumab According to Need: A Treatment for Age-related Macular DegenerationAmerican Journal of Ophthalmology, 2007
- An Optical Coherence Tomography-Guided, Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis) for Neovascular Age-related Macular DegenerationAmerican Journal of Ophthalmology, 2007
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006